Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.0252W HIGH $33.20
Volume
557.96 K
Value Traded
3.39 M
Short % Float
13.76%
-6.02%Week
-40.7%1 Month
-48.35%3 Month
-76.86%6 Month
+32.58%5 Year
+32.58%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
226.83 M
EPS (TTM)
-2.61
P/E Ratio
-
Ent. Value
-61.18 M
Total Shares
36.28 M
Float Shares
20.91 M
Insiders
42.40%
Institutions
68.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
EVMN Catalyst Timeline
Dated clinical, regulatory and corporate events for Evommune, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evommune, Inc.
41Total events
12Upcoming
14Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Event history 26
▲Oral PresentationEVO301Presentation
Late-breaking Phase 2a proof-of-concept data for EVO301 presented at EADV 2026 Congress
moderate-to-severe atopic dermatitissource ↗
▲Biomarker DataEVO301Clinical Data
Biomarker analyses confirm Th2 pathway modulation and broad anti-inflammatory activity (Th1, Th17/22)
moderate-to-severe atopic dermatitissource ↗
▲PK PD DataEVO301Clinical Data
EVO301 favorable PK profile supporting Q4-week dosing and potential every-8-to-12-week maintenance
moderate-to-severe atopic dermatitissource ↗
▲Primary Endpoint MetEVO301Clinical Data
EVO301 met primary endpoint with 55% LS mean EASI reduction vs 22% placebo at Week 12 (p<0.01)
moderate-to-severe atopic dermatitissource ↗
▲Safety Data UpdateEVO301Clinical Data
EVO301 well tolerated with no treatment-related serious/severe AEs and no conjunctivitis
moderate-to-severe atopic dermatitissource ↗
▼Topline ReadoutEVO756Clinical Data
EVO756 Phase 2b topline results in moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▼Primary Endpoint MissedEVO756Clinical Data
EVO756 missed primary endpoint (percent change in EASI at Week 12) in Phase 2b AD trial
moderate-to-severe atopic dermatitissource ↗
▼Program DiscontinuationEVO756Corporate
Evommune does not plan to advance EVO756 in atopic dermatitis
atopic dermatitissource ↗
◆Topline ReadoutEVO756Clinical Data
EVO756 Phase 2b top-line data in moderate-to-severe AD
atopic dermatitissource ↗
▲Manufacturing MilestoneEVO301CMC / Inspection
Subcutaneous formulation work complete for EVO301
▲Enrollment CompleteEVO756Trial
Enrollment completed in Phase 2b trial of EVO756 in AD
atopic dermatitissource ↗
▲First Patient DosedEVO756Trial
First patient dosed in Phase 2b trial of EVO756 for migraine prophylaxis
migrainesource ↗
●Trial InitiationEVO756Trial
EVO756 Phase 2b dose-ranging trial initiated in migraine prophylaxis
migraine prophylaxissource ↗
◆Topline ReadoutEVO756Clinical Data
Top-line results from EVO756 Phase 2b trial in moderate-to-severe chronic spontaneous urticaria
moderate-to-severe chronic spontaneous urticariasource ↗
●Poster PresentationEVO756Presentation
Poster presentation at FOCIS 2026 on shared pathology in CIndU and CSU
chronic inducible urticaria and chronic spontaneous urticariasource ↗
●Poster PresentationEVO756Presentation
Poster presentation at AHS 2026 on MRGPRX2 in migraine
migrainesource ↗
▼Topline ReadoutEVO756Clinical Data
EVO756 Phase 2b top-line results in chronic spontaneous urticaria
chronic spontaneous urticariasource ↗
●Trial InitiationEVO756Trial
Phase 2b trial of EVO756 in migraine prophylaxis to initiate
migraine prophylaxissource ↗
▲Enrollment CompleteEVO756Trial
Enrollment completed in Phase 2b trial of EVO756 in CSU
chronic spontaneous urticariasource ↗
▼Program DiscontinuationEVO756Corporate
Evommune discontinued development of EVO756 in CSU
chronic spontaneous urticariasource ↗
●Poster PresentationEVO301Presentation
Preclinical data presentation at SID 2026 on IL-18 inhibition
atopic dermatitissource ↗
●Trial InitiationEVO756Trial
Phase 2b trial of EVO756 in migraine prophylaxis to initiate in mid-2026
migraine prophylaxissource ↗
▲Preclinical PoCEVO301Preclinical
Positive Phase 2a proof-of-concept data reported for EVO301 in AD
atopic dermatitissource ↗
▲Topline ReadoutEVO301Clinical Data
Positive top-line Phase 2a proof-of-concept data for EVO301 in moderate-to-severe AD reported earlier this year
moderate-to-severe atopic dermatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How EVMN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | EVO301 (SAFA-IL-18BP fusion protein) | Phase 2a data presentation | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$271M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.2x
rNPV / MCap
Top 32%
Micro Cap(rank 212 of 660)
Percentile Rank
Evommune, Inc. carries a moderate pipeline score (43/100), with $1.1B risk-adjusted pipeline value, led by EVO301 in Atopic Dermatitis (AD) (Phase 2), across $73B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EVO301 Monoclonal antibodyCompletedNCT06723405 | Atopic Dermatitis (AD) | Phase 2 | COMPLETED | 71 | Nov 17, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every EVMN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EVO301 | atopic dermatitis | Phase 2a | 2026-10-01 | 55% least-squares (LS) mean reduction in EASI from baseline at Week 12 compared with 22% on placebo (p<0.01); 41% vs. 18% at Week 4; 50% vs. 16% at Week 8; 63% of EVO301-treated patients achieved EASI-50 compared with 23% on placeboRead More | Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Carver KyleOfficer (Chief Financial Officer) | Buy | 1,000 60,335 held | $13.26 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EVMN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.4 % (-55.6 %) | 46.44 M | 3.49 M |
EVMN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVMN ranks across every disease it competes in
Competitive Position is a premium feature
See how EVMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVMN News
EVMN▼ -12.7%on this news
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune, Inc. presented encouraging Phase 2a proof-of-concept data for its drug EVO301 aimed at treating moderate-to-severe atopic dermatitis. This presentation took place during the European Academy of Dermatology and Venereology Congress in Vienna. The results underscore the potential of EVO301 in addressing chronic inflammatory diseases.
Read more →EVMNEvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune, Inc. has announced that it will present Phase 2a trial data for EVO301, aimed at treating moderate-to-severe atopic dermatitis, at the European Academy of Dermatology & Venereology Congress in Vienna. This late-breaking presentation underscores the importance of the findings in the context of chronic inflammatory diseases.
Read more →EVMN▼ -17.1%on this news
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. has announced promising top-line results from its Phase 2b trial of EVO756, an oral MRGPRX2 antagonist for moderate-to-severe atopic dermatitis. The trial was randomized, double-blind, and placebo-controlled, suggesting a robust evaluation of the drug's efficacy and safety. These results may pave the way for further development in chronic inflammatory diseases.
Read more →EVMN▲ +5.2%on this news
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Evommune, Inc. reported its financial results for the second quarter of 2026, highlighting its ongoing development of therapies for chronic inflammatory diseases. The company emphasized the lack of effective first-line oral treatments for patients with atopic dermatitis, which presents a significant opportunity for their products. The business update reflects a positive outlook for the company's future endeavors.
Read more →EVMNEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Evommune has commenced a Phase 2b clinical trial for EVO756, a selective MRGPRX2 antagonist aimed at migraine prophylaxis. The trial will enroll approximately 330 patients and is designed to evaluate the drug's efficacy over 12 weeks. Top-line data is expected in 2027, marking a significant step in addressing unmet needs in migraine treatment.
Read more →EVMN▼ -40.2%on this news
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evommune has announced the top-line results from its EVO756 Phase 2b trial targeting moderate-to-severe chronic spontaneous urticaria. The trial's outcomes are currently being analyzed, but specific details about the results have not been disclosed in the article. Further information may be expected as the company continues its evaluation.
Read more →EVMN▼ -5.6%on this news
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune has reported its financial results for the first quarter of 2026, along with key business highlights. However, the article does not provide specific details about the financial performance or business developments. The lack of information limits the analysis of the company's current standing.
Read more →EVMN▲ +5.9%on this news
Role of MRGPRX2 in Migraine
Evommune, Inc. is advancing its understanding of the role of MRGPRX2 in treating migraines, with its compound EVO756 currently in development for migraine therapy. The company is preparing for a Phase 2b trial to evaluate EVO756's efficacy, supported by promising preclinical data. High patient demand for effective preventative treatments highlights the market potential for EVO756, despite the inherent risks associated with clinical trials and forward-looking statements. The upcoming trial is crucial for assessing the compound's therapeutic benefits in a field with significant unmet needs.
Read more →EVMNEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Evommune is set to host a Key Opinion Leader (KOL) webinar on April 13, 2026. The focus of the webinar will be on the potential of MRGPRX2 inhibition in treating migraines. This event aims to provide insights into the therapeutic prospects of this approach.
Read more →EVMN▲ +6.4%on this news
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Evommune, Inc. reported positive financial results for the fourth quarter and full year 2025, including encouraging top-line data from the Phase 2a trial of EVO301 for atopic dermatitis. The company successfully raised $125 million through a private placement to enhance its cash position and extend its financial runway until 2028. Evommune is advancing its drug development pipeline, with top-line data from ongoing trials expected in 2026. However, the company faces challenges with a significant net loss, indicating the need for sustainable operations as it progresses in clinical trials.
Read more →EVMNEvommune Announces $125 Million Private Placement
Evommune, a clinical-stage biotechnology company, announced a private placement to sell 4,494,279 shares of its common stock for approximately $125 million. The shared price is set at $27.88 each, and the transaction is expected to close around February 17, 2026. The company plans to use the proceeds to advance its clinical development programs and for general corporate purposes. Note that these securities have not been registered under the Securities Act, limiting their immediate sale in certain jurisdictions.
Read more →EVMN▲ +70.9%on this news· ran to +86% by day 3shared move
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. announced positive top-line results from its Phase 2a trial of EVO301 for moderate-to-severe atopic dermatitis. The trial demonstrated significant efficacy with a notable percentage of patients achieving improved scores. The company plans to advance to a Phase 2b trial to optimize dosing and enhance patient outcomes. Full results will be presented at a future scientific conference.
Read more →EVMNEvommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Evommune, Inc. reported its financial results for the third quarter of 2025, disclosing a net loss of $12.5 million. Following the successful completion of its IPO, which raised $172.5 million, the company is well-positioned to advance its lead programs, EVO756 and EVO301, with three Phase 2 data readouts anticipated in 2026. Notably, EVO756 is showing early positive results in treating chronic spontaneous urticaria, while EVO301 is expected to offer more effective treatment for atopic dermatitis. The company continues to explore additional indications for both candidates.
Read more →About Evommune, Inc.
Headquarters1891 PAGE MILL RD, PALO ALTO, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next EVMN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime